




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Matthew C.T. FYFE et al.**Serial No.:** 10/776,584**Attorney Docket No.:** NC-10001**Filed:** February 1, 2004**Group Art No.:** unassigned**Examiner:** unassigned**Title:** TRI(CYCLO)SUBSTITUTED
AMIDE COMPOUNDS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: **Mail Stop Amendment**, Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

OSI Pharmaceuticals, Inc.

By


Shu M. Lee

Date

June 24, 2004

Mail Stop Amendment

Commissioner for Patents

U.S. Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants respectfully submit the documents itemized in the enclosed Form 1449 to the Examiner's attention. Copies of the documents, except for U.S. Patent documents – which the Patent Office has instructed Applicants not to submit, are also enclosed for the Examiner's review. Applicants respectfully request the Examiner initial the form and return a copy to the Applicant to indicate each document has been considered.

The significance of foreign language documents WO 03/080585 and WO 04/097824 is described in the specification at page 2, lines 26-31.

This IDS is being submitted before issuance of any Office Action on the merits. Accordingly, no fee is needed. Nevertheless, the Examiner is authorized to charge any deficiencies in fees and credit any overpayment to OSI Pharmaceuticals, Inc. Deposit Account No. 502783.

Attorney for Applicants can be reached at the telephone number and address below.

I hereby certify
deposited
sufficient
address
1450,
appearing below.

being
with
envelope
Box
date

OSI PHARMACEUTICALS, Inc.

By _____ Date _____

June 24, 2004
OSI Pharmaceuticals, Inc.
58 South Service Road, Suite 110
Melville, NY 11747

Respectfully submitted,



Shu M. Lee
Attorney for Applicants
Registration No. 41,147
Telephone No. (631) 962-2056
or (516) 924-4035
Fax No. (631) 752-3880

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

OSI PHARMACEUTICALS, Inc.

By Shu M. Lee Date 24 June 2004



Form TO-1449

**LIST OF PATENTS AND
PUBLICATIONS FOR
APPLICANT'S INFORMATION
DISCLOSURE STATEMENT**
(Use as many sheets as necessary)

Complete If Known

				Application Number	10/776,584
				Filing Date	February 1, 2004
				First Named Inventor	Matthew C.T. FYFE
				Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	2	Attorney Docket No.	NC-10001

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REFERENCE DESIGNATION	DOCUMENT NUMBER	PUBLICATION OR ISSUE DATE	INVENTOR	CLASS/ SUBCLASS
	A1	6,320,050	11-20-2001	Bizzarro	
	A2	6,353,111	03-05-2002	Corbett	
	A3	6,369,232	04-09-2002	Sidduri	
	A4	6,384,220	05-07-2002	Corbett	
	A5	6,388,071	05-14-2002	Mahaney	
	A6	6,388,088	05-14-2002	Siddori	
	A7	6,433,188	08-13-2002	Corbett	
	A8	6,441,180	08-27-2002	Sidduri	
	A9	6,441,184	08-27-2002	Corbett	
	A10	6,448,399	09-10-2002	Corbett	
	A11	6,482,951	11-19-2002	Guertin	
	A12	6,486,184	11-26-2002	Kester	
	A13	6,489,485	12-03-2002	Bizzarro	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	REFERENCE DESIGNATION	DOCUMENT NUMBER	PUBLICATION DATE	APPLICANT	COUNTRY
	B1	WO 04/050645	06-17-2004	Novartis AG	PCT
	B2	WO 00/058293	10-05-2000	F. Hoffman-La Roche	PCT
	B3	WO 01/044216	06-21-2001	F. Hoffman-La Roche	PCT
	B4	WO 01/083465	11-08-2001	F. Hoffman-La Roche	PCT
	B5	WO 01/083478	11-08-2001	F. Hoffman-La Roche	PCT
	B6	WO 01/085706	11-15-2001	F. Hoffman-La Roche	PCT
	B7	WO 01/085707	11-15-2001	F. Hoffman-La Roche	PCT
	B8	WO 02/008209	01-31-2002	F. Hoffman-La Roche	PCT
	B9	WO 02/014312	02-21-2002	F. Hoffman-La Roche	PCT
	B10	WO 02/046173	06-13-2002	F. Hoffman-La Roche	PCT
	B11	WO 02/048106	06-20-2002	F. Hoffman-La Roche	PCT
	B12	WO 03/000262	01-03-2003	Astrazeneca AB	PCT
	B13	WO 03/000267	01-03-2003	Astrazeneca AB	PCT

EXAMINER INITIAL	REFERENCE DESIGNATION	OTHER ART (Include Author, Title, Date, Pages, etc.)
	C1	R.L. Printz et al., Ann. Rev. Nutrition, 13:463-496(1993)
	C2	Y.Liang et al., Biochem. J., 309:167-173(1995)
	C3	H.B.T. Christesen et al., Diabetes, 51:1240-1246(2002)
	C4	Printout of Delphion Abstract for WO 03/97824

EXAMINER	Date Considered:
----------	------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449				Complete If Known	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use as many sheets as necessary)				Application Number	10/776,584
				Filing Date	February 1, 2004
				First Named Inventor	Matthew C.T. FYFE
				Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	of	2	Attorney Docket No.	NC-10001

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REFERENCE DESIGNATION	DOCUMENT NUMBER	PUBLICATION OR ISSUE DATE	INVENTOR	CLASS/SUBCLASS
	A14	6,610,846	08-26-2003	Bizzarro	
	A15	2003/0219887	11-27-2003	Corbett	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	REFERENCE DESIGNATION	DOCUMENT NUMBER	PUBLICATION DATE	APPLICANT	COUNTRY
	B14	WO 03/015774	02-27-2003	Astrazeneca AB	PCT
	B15	WO 03/047626	06-12-2003	Novo Nordisk	PCT
	B16	WO 03/055482	07-10-2003	Novo Nordisk	PCT
	B17	WO 03/080585	10-02-2003	Banyu Pharm.	PCT
	B18	WO 03/095438	11-20-2003	F. Hoffman-La Roche	PCT
	B19	WO 03/097824	11-27-2003	Banyu Pharm.	PCT
	B20	WO 04/002481	01-08-2004	Novo Nordisk	PCT

EXAMINER INITIAL	REFERENCE DESIGNATION	OTHER ART (Include Author, Title, Date, Pages, etc.)
	C5	Printout of Delphion Abstract for WO 03/080585

EXAMINER	Date Considered:
----------	------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.